Today, plant based vaccine developer Medicago and GSK announce positive phase 3 efficacy and safety results for their adjuvanted plant-based COVID-19 vaccine candidate.
With full results of the Phase 3 study expected to be released soon, the trial was conducted in over 24,000 subjects, 18 years of age and over, across six countries. Based on this most recent trial Medicago will be seeking regulatory approval from Health Canada which, if successful, would make it the world’s first plant-based vaccine against COVID-19.
As a global leader in controlled environment technology, both Conviron and Argus have supplied Medicago with a vast array of controlled environment equipment for control systems, germination, incubation and R&D processes. Much of which did not fit into standard product designs and needed to be custom engineered and manufactured to meet Medicago’s unique requirements. As a result of this collaboration our team has delivered some of its most advanced controlled environment plant growth equipment to date, all of which integrates seamlessly into Medicago’s existing facilities in both Quebec and Raleigh-Durham.
Medicago is on a mission to improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. Proudly rooted in Quebec, with manufacturing capacity in both Canada and the US, Medicago has a passionate and curious team of over 500 scientific experts and employees dedicated to using technology to provide rapid responses to emerging global health challenges worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. For more information: www.medicago.com
Mitsubishi Tanabe Pharma Corporation (MTPC) Group, the majority parent company of Medicago, is headquartered in Osaka and is one of Japan's largest pharmaceutical companies. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. For further information please visit https://www.mt-pharma.co.jp/e/
Adapted from the original stories: